Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
暂无分享,去创建一个
Karla P. Zepeda | Christina C. Chang | Kamil H A Kim | W. Self | N. Gerry | A. Ginde | H. Günthard | R. Paredes | R. Dewar | S. Vogel | V. Natarajan | A. Phillips | J. Lundgren | K. Syrigos | A. Weintrob | J. Neaton | A. Kelleher | B. Grund | C. Reilly | D. Murray | D. Lye | D. Vock | N. Koulouris | E. Mylonakis | Z. Barmparessou | I. Kalomenidis | G. Grandits | D. Braun | S. Bhagani | A. Rodger | G. Touloumi | A. Gelijns | B. Trautner | I. Kimuli | B. Young | A. Bednarska | F. Hudson | K. Knowlton | E. Higgs | A. Babiker | S. Pett | C. Barkauskas | M. Teitelbaum | D. Vallée | N. Engen | L. Leither | P. Legenne | P. Robinson | Adriana Sánchez | U. Sandkovsky | G. Poulakou | K. Protopapas | C. Chang | Mamta K. Jain | M. Padilla | Sylvain Laverdure | V. Menon | M. T. Rehman | H. Highbarger | Page E. Crew | E. Almasri | A. Osuji | Srikanth Ramachandruni | Samuel M Brown | R. Chandra | Peter Chen | K. Shaw-Saliba | Francis Kiweewa | A. Vekstein | S. Vasudeva | R. Gottlieb | V. Rapti | Ralph Rogers | B. Thompson | T. Jensen | C. North | E. Mylona | F. Shehadeh | J. Overcash | M. Waters | V. Davey | Adam Schechner | T. Hatlen | V. Kan | H. Lane | G. Matthews | S. Nagy-Agren | M. Matthay | Shweta Sharma | Amiran Baduashvili | A. Hughes | Evan X. Accardi | N. Mosaly | S. H. Diong | J. Badrock | Joseph K. Lutaakome | L. Siegel | Matthew Kaczynski | Rubria Marines‐Price | S. Torbati | Nicholus Sebudde | Eriobu Nnakelu | Robert Kidega | Negin Atri | D. Looney | H. H. Nguyen | Lindsay M. Leither | Samuel M. Brown | M. Jain | J. Lutaakome | S. Laverdure | Daniel D. Murray | Michael Matthay | Page E Crew | Evan Accardi | Helene Highbarger
[1] Christina C. Chang,et al. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial , 2022, The Lancet Respiratory Medicine.
[2] Shinji Watanabe,et al. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant , 2022, The New England journal of medicine.
[3] John D. Davis,et al. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. , 2022, JAMA.
[4] M. Landray,et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.
[5] M. Stumpp. Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants , 2021 .
[6] P. Pang,et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. , 2021, The New England journal of medicine.
[7] Samuel M. Brown,et al. Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) , 2021, Clinical trials.
[8] John D. Davis,et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 , 2021, The New England journal of medicine.
[9] D. Skovronsky,et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 , 2021, The New England journal of medicine.
[10] P. Shanley,et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 , 2021, Evidence-Based Practice.
[11] Karen L. Price,et al. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. , 2021, JAMA.
[12] Samuel M. Brown,et al. Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) , 2020, medRxiv.
[13] Samuel M. Brown,et al. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 , 2020, The New England Journal of Medicine.
[14] John D. Davis,et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 , 2020, The New England journal of medicine.
[15] Michael T. Stumpp,et al. Beyond Antibodies: The DARPin® Drug Platform , 2020, BioDrugs.
[16] Mike Clarke,et al. A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.
[17] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[18] R. Schooley,et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial , 2019, The Lancet. Respiratory medicine.
[19] A. Plückthun,et al. High-affinity binders selected from designed ankyrin repeat protein libraries , 2004, Nature Biotechnology.
[20] M. Wood,et al. Analysis and interpretation of data. , 1978, The Journal of family practice.